Best hospitals in the United States for ovarian cancer: an evidence-based guide

The phrase “best hospitals in the United States for ovarian cancer” can refer to highly ranked cancer hospitals, high-volume gynecologic oncology programs, or centers recognized specifically for ovarian and uterine cancer surgery. Available research shows that no single hospital is universally best for every patient because treatment decisions depend on stage, tumor type, surgical needs, genetic findings, clinical-trial options, and location. 10

Hospitals recognized for ovarian cancer surgery

Castle Connolly’s 2026 list, reported by Becker’s Oncology, identifies 23 hospitals recognized for uterine and ovarian cancer surgery. Its methodology includes all-payer claims data, clinical outcome data, and review by a physician-led research team. The hospitals are listed alphabetically rather than ranked from first to last, so the list should not be interpreted as a performance order or as proof that one institution is superior for every ovarian cancer case. 1

National cancer centers and ranking context

MD Anderson Cancer Center in Houston is an NCI-designated Comprehensive Cancer Center devoted to cancer care, research, education, and prevention. The National Cancer Institute states that U.S. News & World Report has named MD Anderson the nation’s top hospital for cancer care and that it has appeared among the top two every year since the rankings began in 1990. 2

U.S. News rankings provide broad cancer-care context, but they are not ovarian-cancer-specific surgical outcome reports. A 2026 report on the 2026-2027 rankings placed MD Anderson first and Memorial Sloan Kettering Cancer Center second for cancer care, with Dana-Farber Brigham Cancer Center, Mayo Clinic, Massachusetts General Hospital, Johns Hopkins Hospital, Hospital of the University of Pennsylvania, Northwestern Memorial Hospital, Stanford Hospital, Mount Sinai Hospital, and UCSF Medical Center also appearing in the top group. 3

Why gynecologic oncology specialization matters

Ovarian cancer care commonly involves gynecologic oncologists, medical oncologists, pathologists, genetic counselors, and other specialists. The relevant expertise includes diagnosis, staging, surgery, chemotherapy, targeted therapy, immunotherapy, genetic testing, and tumor testing. A coordinated team is particularly important when disease involves the pelvis, abdomen, fallopian tubes, or peritoneum. 9

High patient volume can be one useful question when comparing programs, although volume alone does not establish superior results. Penn Medicine reports that its surgical team treats a high volume of ovarian cancer patients and offers treatments that may include chemotherapy before surgery, combination drug therapy, HIPEC in selected circumstances, immunotherapy, and radiation. The appropriate combination depends on cancer type, stage, grade, visible tumor burden, genetic results, age, and general health. 5

Programs with distinctive ovarian cancer services

Swedish Cancer Institute in Seattle describes a multidisciplinary ovarian cancer program involving advanced imaging, treatment options, clinical trials, and support services. Swedish also reports that its gynecologic cancer program is the fourth-highest-volume ovarian cancer center in the United States. This is an institution-reported volume statement, not a national ranking independently verified in the supplied material. 4

Tampa General Hospital, in partnership with USF Health Morsani College of Medicine, received a Surgical Review Corporation Center of Excellence designation in Gynecologic Surgical Oncology in 2026. The reported recognition involved the hospital’s cancer and women’s institutes and reflects a surgical quality designation, not a claim that it is the best ovarian cancer hospital nationally. 7

Research, trials, and precision-oriented treatment

Research access can be an important differentiator between hospitals. MD Anderson reported investing $1.3 billion in research in fiscal year 2025, awarding more than 140 patents, and testing 70% of cancer drugs approved by the Food and Drug Administration that year. These institutional figures describe research activity and do not guarantee that a particular ovarian cancer patient will qualify for a study or benefit from an investigational treatment. 2

Clinical-trial availability should be evaluated alongside eligibility criteria, treatment history, tumor genetics, travel requirements, and possible additional monitoring. The NCI identifies NCI-designated cancer centers as institutions providing leadership in cancer research and patient care. The NCI’s ovarian cancer information also covers diagnosis, treatment, clinical trials, and research developments, making those factors relevant when assessing comprehensive care. 10

How to compare hospitals responsibly

A practical comparison begins with confirmation that the institution has gynecologic oncology specialists who routinely treat ovarian, fallopian-tube, and primary peritoneal cancers. Questions may address the surgeon’s experience with complex cytoreductive procedures, how pathology is reviewed, whether genetic and tumor testing are available, how treatment conferences operate, and which clinical trials match the diagnosis. ColumbiaDoctors describes treatment as potentially involving surgery, chemotherapy, targeted therapy, genetic testing, tumor testing, and clinical trials. 9

Patients and families should also examine nonclinical constraints, including insurance participation, referral requirements, travel, lodging, caregiver needs, second-opinion processes, and continuity between surgery and systemic treatment. Awards and rankings may use different methodologies, time periods, and definitions of quality. Karmanos Cancer Institute, for example, reported a 2026 Women’s Choice Award placing it in the top 2% of more than 4,600 U.S. hospitals offering cancer services, while noting its NCI designation and stand-alone cancer hospital status. 8

What a hospital ranking cannot establish

A national ranking cannot predict an individual outcome, replace review of medical records, or determine whether a hospital is appropriate for a rare tumor subtype or a recurrence. Even a highly regarded center may not have a convenient trial, an available specialist, or an insurance arrangement suitable for a particular patient. Treatment plans can change after surgical findings, pathology review, genetic testing, or assessment of overall health. 5

The most defensible interpretation of the available evidence is that leading options include major NCI-designated and academic cancer centers, hospitals recognized for ovarian surgery, and regional programs with documented gynecologic oncology expertise. A careful decision weighs relevant surgical experience, coordinated specialty care, research access, quality information, and practical feasibility instead of relying on a single “best hospital” label. 1

Sources

1. Becker’s Oncology, “Top 23 hospitals for uterine, ovarian cancer surgery: Castle Connolly”
2. National Cancer Institute, “UT MD Anderson”
3. Healio, “UT MD Anderson once again named nation’s best cancer hospital”
4. Swedish Cancer Institute, “Ovarian Cancer Care”
5. Penn Medicine, “Ovarian Cancer Treatment”
6. Verywell Health, “Top Hospitals for Cancer Care in the U.S.”
7. Tampa General Hospital and USF Health, gynecologic surgical oncology recognition report
8. Karmanos Cancer Institute, “2026 Women’s Choice Award”
9. ColumbiaDoctors, “Ovarian Cancer: Symptoms and Treatment”
10. National Cancer Institute, “NCI-Designated Cancer Centers”